Abstracts tagged "Cardiovascular"

Abstract Number: 1753 • ACR Convergence 2021
Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors
Laurence Magder¹, Michelle Petri² and Daniel Goldman², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In SLE, treatment with hydroxychloroquine (HCQ) has been shown to be associated with reduced SLE flares and reduced risk of damage in several different…
Abstract Number: 0276 • ACR Convergence 2021
Pulse Pressure as a Predictor of Carotid Plaque in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Alejandra Rodriguez-Romero, Julieta Loya-Acosta, Alejandro Meza-Garza, Jesus Cardenas-de La Garza, Salvador Lugo-Perez and Jessica Castillo-Treviño, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Pulse pressure (PP) is defined as the difference between systolic and diastolic blood pressure and represents arterial compliance and reflective properties of blood flow.…
Abstract Number: 0642 • ACR Convergence 2021
Prevalence and Risk Factors for Cardio-metabolic Abnormalities in Patients with Inflammatory Arthritis Attending Cardio-rheumatology Primary Prevention Clinics
Lihi Eder¹, Shadi Akhtari², Dana Jerome¹, Jacob Udell¹, Patrick Lawler¹, Paula Harvey³ and Bindee Kuriya⁴, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, University of Toronto, North York, ON, Canada, ³Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Cardio-metabolic abnormalities are common in patients with inflammatory arthritis (IA) but tend to be under-recognized and under-treated. We aimed to compare the prevalence and…
Abstract Number: 1093 • ACR Convergence 2021
Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
Bindee Kuriya¹, Shadi Akhtari², Mohammad Movahedi³, Jacob Udell⁴, Patrick Lawler⁴, Paula Harvey⁵ and Lihi Eder⁴, ¹University of Toronto - Toronto, Toronto, ON, Canada, ²Women's College Hospital, University of Toronto, North York, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Inflammatory arthritis (IA) is associated with cardiovascular disease (CVD). Cardiac biomarkers may assist with CVD risk stratification. We aimed to estimate the prevalence, and…
Abstract Number: 1835 • ACR Convergence 2021
Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies
Joseph Merola¹, Iain McInnes², Atul Deodhar³, Erhard Quebe-Fehling⁴, Maher Aassi⁴, Michael Peine⁴ and Nehal Mehta⁵, ¹Department of Dermatology and Department of Medicine, Division of Rheumatology; Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Psoriasis (PsO), Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxSpA) are chronic immune-mediated inflammatory diseases (IMIDs) requiring long-term treatment. Systemic inflammation in these IMIDs is…
Abstract Number: L08 • ACR Convergence 2020
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Thomas MacDonald¹, Isla Mackenzie¹, George Nuki² and Ian Ford³, ¹University of Dundee, Dundee, Scotland, United Kingdom, ²University of Edinburgh, Edinburgh, Scotland, United Kingdom, ³University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…
Abstract Number: 0059 • ACR Convergence 2020
EHR-Supported Staff Protocol Improves Smoking Cessation in a Diverse Rheumatology Clinic: Results of Quit Connect Dissemination Project
Jennifer Brandt¹, S. Sam Lim¹, Edmond Ramly², Monica Messina³ and Christie Bartels⁴, ¹Emory University, Atlanta, GA, ²University of Wisconsin School of Medicine and Public Health, Department of Family Medicine and Community Health;, Madison, ³University of Wisconsin School of Medicine and Public Health, Department of Medicine, Rheumatology Division, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: Smoking is a key risk factor for rheumatologic conditions such as rheumatoid arthritis and lupus that disproportionately impacts disadvantaged patients and predicts worse outcomes.…
Abstract Number: 0786 • ACR Convergence 2020
A Combination of Dimensionality Reduction Techniques Reveals Novel HLA-DR+ ‘Candidate’ Antigen-Presenting Cell Subsets (cAPC) in Patients with Rheumatoid Arthritis (RA)
Christian Geier¹, Jon Giles¹, Samantha Gaines², Christopher Depender¹, Joan Bathon¹ and Robert Winchester¹, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: The presentation of MHC-peptide complexes to T lymphocytes via antigen-presenting cells (APC) is a crucial step in the initiation of immune responses. Dendritic cells…
Abstract Number: 1190 • ACR Convergence 2020
Sex Differences in Cardiovascular Disease Prevention in Patients with Rheumatoid Arthritis: World-wide Data from the SURF-RA
Elena Myasoedova¹, Cynthia Crowson², Joseph Sexton³, Silvia Rollefstad³ and Anne Grete Semb⁴, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Rheumatoid arthritis (RA) is associated with 2-fold increase in risk of cardiovascular (CV) disease. Extensive evidence from the general population suggests that control of…
Abstract Number: 1474 • ACR Convergence 2020
Early Peak of Cardiovascular Events Occurs Equally in Caucasians and African-American SLE but Is Attributed to Different Risk Factors
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: The classic bimodal pattern of morbidity/mortality in SLE highlighted that cardiovascular events occurred later in the natural history of SLE (Urowitz & Gladman. J…
Abstract Number: 1937 • ACR Convergence 2020
Aortic Aneurysm in Giant Cell Arteritis: A Nationwide Analysis
Jiayi Zheng¹, Ruoning Ni², Yan Tang³ and Liangjing Lu⁴, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ²St. Agnes Hospital, Baltimore, MD, ³Department of Stomatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory vasculopathy affecting primarily medium and large sized arteries. Previous studies have demonstrated a higher prevalence of aortic…
Abstract Number: 0239 • ACR Convergence 2020
Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials
Christina Charles-Schoeman¹, Sang-Cheol Bae², Arvind Chopra³, Stanley Cohen⁴, Jeffrey R Curtis⁵, Jacques-Eric Gottenberg⁶, Edward C Keystone⁷, Kunihiro Yamaoka⁸, Peter Nash⁹, J-Abraham Simon-Campos¹⁰, William Stohl¹¹, Michael Weinblatt¹², Rene Westhovens¹³, Jeff Siegel¹⁴, Iyabode Tiamiyu¹⁴, Lei Ye¹⁴, Deyuan Jiang¹⁴, Franziska Matzkies¹⁴, Angelika Jahreis¹⁴, John S. Sundy¹⁴ and Jon Giles¹⁵, ¹University of California, Los Angeles, Los Angeles, CA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Center for Rheumatic Diseases, Pune, India, ⁴University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Strasbourg University Hospital, Strasbourg, France, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁹School of Medicine Griffith University, Brisbane, Queensland, Australia, ¹⁰Köhler & Milstein Research, Mérida, Mexico, ¹¹University of Southern California Keck School of Medicine, Los Angeles, CA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁴Gilead Sciences, Inc., Foster City, CA, ¹⁵Columbia University, New York, NY
Background/Purpose: Filgotinib (FIL)—an oral, selective Janus kinase 1 inhibitor (JAKi)—improved RA signs and symptoms in three phase 3 trials. Despite the efficacy of FIL and…
Abstract Number: 0789 • ACR Convergence 2020
Matrix Gla Protein (MGP) Modified with Malondialdehyde/Acetaldehyde Is Increased in Rheumatoid Arthritis and Cardiovascular Patients
Xiarepati Tieliwaerdi¹, Nozima Aripova¹, Michael Duryee¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased cardiovascular disease (CVD) burden, dramatically increasing the risk of mortality. Circulating antibodies to Malondialdehyde-Acetaldehyde (MAA) modified…
Abstract Number: 1191 • ACR Convergence 2020
Specificity for Inflammatory Pathways Associated with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Brittany Weber¹, Zeling He¹, Sicong Huang¹, Daniel H. Solomon², Elena Massarotti¹, Charlotte Golnik¹, Thany Seyok¹, Seth Brownmiller¹, Laurel Martell¹, Leann Barrett¹, Courtney Bibbo¹, Marcy Bolster³, Marcelo DiCarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Concord, MA
Background/Purpose: Coronary microvascular disease (CMD) is associated with increased mortality in RA independent of traditional cardiovascular (CV) risk factors. Inflammation likely plays an important role…
Abstract Number: 1510 • ACR Convergence 2020
Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
Yevgeniya Gartshteyn¹, Adam Mor², Daichi Shimbo², Leila Khalili³, Teja Kapoor⁴, Laura Geraldino-Pardilla⁵, Roberta Vezza Alexander⁶, Thierry Dervieux⁷ and Anca Askanase², ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University Medical Center, New Haven, CT, ⁴Columbia University College of Physicians and Surgeons, Leonia, NJ, ⁵Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, ⁶Exagen Inc, Vista, CA, ⁷Prometheus Biosciences Inc, Irvine, CA
Background/Purpose: Platelets have a well-defined role in arterial thrombosis, and platelet-bound complement activation products (PC4d) correlate with vascular thromboses in patients with Systemic Lupus Erythematosus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].